Education
About Us
Working with TipRanks
Follow Us
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
Total Valuation
Unicycive Therapeutics has a market cap or net worth of $118.63M. The enterprise value is $36.34M.
Market Cap$118.63M
Enterprise Value$36.34M
Share Statistics
Unicycive Therapeutics has 21,491,396 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,491,396
Owned by Insiders25.67%
Owned by Institutions0.15%
Financial Efficiency
Unicycive Therapeutics’s return on equity (ROE) is -4.94 and return on invested capital (ROIC) is -391.48%.
Return on Equity (ROE)-4.94
Return on Assets (ROA)-1.16
Return on Invested Capital (ROIC)-391.48%
Return on Capital Employed (ROCE)-4.26
Revenue Per Employee0.00
Profits Per Employee-1.67M
Employee Count22
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Unicycive Therapeutics is ―. Unicycive Therapeutics’s PEG ratio is -0.00429.
PE Ratio―
PS Ratio0.00
PB Ratio7.16
Price to Fair Value7.16
Price to FCF-1.86
Price to Operating Cash Flow-3.23
PEG Ratio-0.00429
Income Statement
In the last 12 months, Unicycive Therapeutics had revenue of 0.00 and earned -36.73M in profits. Earnings per share was -5.60.
Revenue0.00
Gross Profit0.00
Operating Income-32.12M
Pretax Income-36.73M
Net Income-36.73M
EBITDA-36.23M
Earnings Per Share (EPS)-5.60
Cash Flow
In the last 12 months, operating cash flow was -29.83M and capital expenditures -46.00K, giving a free cash flow of -29.88M billion.
Operating Cash Flow-29.83M
Free Cash Flow-29.88M
Free Cash Flow per Share-1.39
Dividends & Yields
Unicycive Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-17.70%
50-Day Moving Average4.91
200-Day Moving Average5.30
Relative Strength Index (RSI)58.67
Average Volume (3m)483.58K
Important Dates
Unicycive Therapeutics upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Unicycive Therapeutics as a current ratio of 1.28, with Debt / Equity ratio of 0.71%
Current Ratio1.28
Quick Ratio1.28
Debt to Market Cap<0.01
Net Debt to EBITDA0.70
Interest Coverage Ratio-452.35
Taxes
In the past 12 months, Unicycive Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Unicycive Therapeutics EV to EBITDA ratio is -0.77, with an EV/FCF ratio of -0.97.
EV to Sales0.00
EV to EBITDA-0.77
EV to Free Cash Flow-0.97
EV to Operating Cash Flow-0.97
Balance Sheet
Unicycive Therapeutics has $42.70M in cash and marketable securities with $265.00K in debt, giving a net cash position of $42.43M billion.
Cash & Marketable Securities$42.70M
Total Debt$265.00K
Net Cash$42.43M
Net Cash Per Share$1.97
Tangible Book Value Per Share$1.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Unicycive Therapeutics is $36.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$36.60
Price Target Upside524.57% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast66.05%